Hana Initiates Marqibo Phase II Trial in Relapsed/Refractory ALL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

Hana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.

SOUTH SAN FRANCISCO, California—Hana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma